ATOSSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ATOSSA THERAPEUTICS, INC. (ATOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-07
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-25 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-25 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-04-01 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-22 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-31 | |||
| 2019-12-31 | 0.00% 10-K · filed 2020-03-26 | |||
| 2018-12-31 | 0.00% 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |